These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 32851765)
1. Prognostic value of nutritional impairment on treatment-related toxicity and survival in patients with nasopharyngeal carcinoma taking normal nutrition before radiotherapy. Su L; Lin Q; Li R; Hua Y; Zhang H; Song X; Ye J; Zhang W; Hong J Head Neck; 2020 Dec; 42(12):3580-3589. PubMed ID: 32851765 [TBL] [Abstract][Full Text] [Related]
2. Modified-Nutrition Index is a Significant Prognostic Factor for the Overall Survival of the Nasopharyngeal Carcinoma Patients who Undergo Intensity-modulated Radiotherapy. Hong JS; Hua YJ; Su L; Zhang HR; Lv WL; Chen XY; Tian J; Zhang WJ Nutr Cancer; 2017 Oct; 69(7):1011-1018. PubMed ID: 28937797 [TBL] [Abstract][Full Text] [Related]
3. Construction of a comprehensive nutritional index and its correlation with quality of life and survival in patients with nasopharyngeal carcinoma undergoing IMRT: A prospective study. Deng J; He Y; Sun XS; Li JM; Xin MZ; Li WQ; Li ZX; Nie S; Wang C; Li YZ; Chen LP; Chen LM; Zhu SH; Li JW; Hu W; Fan YY; Guo SS; Mai HQ Oral Oncol; 2019 Nov; 98():62-68. PubMed ID: 31541928 [TBL] [Abstract][Full Text] [Related]
4. The Characteristics and Survival Outcomes in Patients Aged 70 Years and Older with Nasopharyngeal Carcinoma in the Intensity-Modulated Radiotherapy Era. Jin YN; Zhang WJ; Cai XY; Li MS; Lawrence WR; Wang SY; Mai DM; Du YY; Luo DH; Mo HY Cancer Res Treat; 2019 Jan; 51(1):34-42. PubMed ID: 29409313 [TBL] [Abstract][Full Text] [Related]
5. Significance of boost dose for T4 nasopharyngeal carcinoma with residual primary lesion after intensity-modulated radiotherapy. Fei Z; Xu T; Qiu X; Li M; Chen T; Li L; Huang C; Chen C J Cancer Res Clin Oncol; 2021 Jul; 147(7):2047-2055. PubMed ID: 33392660 [TBL] [Abstract][Full Text] [Related]
6. Superiority of intensity-modulated radiation therapy in nasopharyngeal carcinoma with skull-base invasion. Liao S; Xie Y; Feng Y; Zhou Y; Pan Y; Fan J; Mi J; Qin X; Yao D; Jiang W J Cancer Res Clin Oncol; 2020 Feb; 146(2):429-439. PubMed ID: 31677113 [TBL] [Abstract][Full Text] [Related]
7. Effect of nutritional status before radiotherapy on radiation-induced acute toxicities in patients with nasopharyngeal carcinoma. Song X; Su L; Lin Q; Liu S; Zhang W; Hong J Head Neck; 2023 Mar; 45(3):620-628. PubMed ID: 36600471 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of intensity-modulated radiotherapy alone versus intensity-modulated radiotherapy plus chemotherapy for treatment of intermediate-risk nasopharyngeal carcinoma. Aftab O; Liao S; Zhang R; Tang N; Luo M; Zhang B; Shahi S; Rai R; Ali J; Jiang W Radiat Oncol; 2020 Mar; 15(1):66. PubMed ID: 32178698 [TBL] [Abstract][Full Text] [Related]
9. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities. Sun X; Su S; Chen C; Han F; Zhao C; Xiao W; Deng X; Huang S; Lin C; Lu T Radiother Oncol; 2014 Mar; 110(3):398-403. PubMed ID: 24231245 [TBL] [Abstract][Full Text] [Related]
10. Prognostic factors of 305 nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy. Han L; Lin SJ; Pan JJ; Chen CB; Zhang Y; Zhang XC; Liao XY; Chen QS Chin J Cancer; 2010 Feb; 29(2):145-50. PubMed ID: 20109341 [TBL] [Abstract][Full Text] [Related]
11. Endoscopic surgery compared with intensity-modulated radiotherapy in resectable locally recurrent nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial. Liu YP; Wen YH; Tang J; Wei Y; You R; Zhu XL; Li J; Chen L; Ling L; Zhang N; Zou X; Hua YJ; Chen YM; Chen L; Lu LX; Chen MY; Wen WP Lancet Oncol; 2021 Mar; 22(3):381-390. PubMed ID: 33600761 [TBL] [Abstract][Full Text] [Related]
12. Nasopharyngeal carcinoma treated with intensity-modulated radiotherapy: clinical outcomes and patterns of failure among subsets of 8th AJCC stage IVa. Huang CL; Guo R; Li JY; Xu C; Mao YP; Tian L; Lin AH; Sun Y; Ma J; Tang LL Eur Radiol; 2020 Feb; 30(2):816-822. PubMed ID: 31650266 [TBL] [Abstract][Full Text] [Related]
13. Update report of T4 classification nasopharyngeal carcinoma after intensity-modulated radiotherapy: an analysis of survival and treatment toxicities. Cao CN; Luo JW; Gao L; Yi JL; Huang XD; Wang K; Zhang SP; Qu Y; Li SY; Xiao JP; Zhang Z; Xu GZ Oral Oncol; 2015 Feb; 51(2):190-4. PubMed ID: 25434585 [TBL] [Abstract][Full Text] [Related]
14. The value of the Prognostic Nutritional Index (PNI) in predicting outcomes and guiding the treatment strategy of nasopharyngeal carcinoma (NPC) patients receiving intensity-modulated radiotherapy (IMRT) with or without chemotherapy. Miao J; Xiao W; Wang L; Han F; Wu H; Deng X; Guo X; Zhao C J Cancer Res Clin Oncol; 2017 Jul; 143(7):1263-1273. PubMed ID: 28247035 [TBL] [Abstract][Full Text] [Related]
15. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost. Ou X; Zhou X; Shi Q; Xing X; Yang Y; Xu T; Shen C; Wang X; He X; Kong L; Ying H; Hu C Oncotarget; 2015 Nov; 6(35):38381-97. PubMed ID: 26485757 [TBL] [Abstract][Full Text] [Related]
16. Comparison of the seventh and eighth editions of the UICC/AJCC staging system for nasopharyngeal carcinoma: analysis of 1317 patients treated with intensity-modulated radiotherapy at two centers. Yang XL; Wang Y; Liang SB; He SS; Chen DM; Chen HY; Lu LX; Chen Y BMC Cancer; 2018 May; 18(1):606. PubMed ID: 29843648 [TBL] [Abstract][Full Text] [Related]
17. Effect of adaptive replanning in patients with locally advanced nasopharyngeal carcinoma treated by intensity-modulated radiotherapy: a propensity score matched analysis. Luo Y; Qin Y; Lang J Clin Transl Oncol; 2017 Apr; 19(4):470-476. PubMed ID: 27718153 [TBL] [Abstract][Full Text] [Related]
18. Survival impact of radiotherapy interruption in nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data intelligence platform-based analysis. Yao JJ; Zhang F; Gao TS; Zhang WJ; Lawrence WR; Zhu BT; Zhou GQ; Ma J; Wang SY; Sun Y Radiother Oncol; 2019 Mar; 132():178-187. PubMed ID: 30448002 [TBL] [Abstract][Full Text] [Related]
19. Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: A 10-year experience with a large cohort and long follow-up. Zhang MX; Li J; Shen GP; Zou X; Xu JJ; Jiang R; You R; Hua YJ; Sun Y; Ma J; Hong MH; Chen MY Eur J Cancer; 2015 Nov; 51(17):2587-95. PubMed ID: 26318726 [TBL] [Abstract][Full Text] [Related]
20. A retrospective study comparing the outcomes and toxicities of intensity-modulated radiotherapy versus two-dimensional conventional radiotherapy for the treatment of children and adolescent nasopharyngeal carcinoma. Qiu WZ; Peng XS; Xia HQ; Huang PY; Guo X; Cao KJ J Cancer Res Clin Oncol; 2017 Aug; 143(8):1563-1572. PubMed ID: 28342002 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]